Chlamydia LPS antibody | CF 6J12
Mouse anti Chlamydia LPS antibody, clone CF 6J12 (MCA2718) used to identify chlamydial inclusions in Hep-2 cells by immunofluorescence.
Image caption:
G3BP1 is accumulated around the chlamydial inclusion in Cp. psittaci infected Hep-2 cells.
Hep-2 cells were infected with Cp. psittaci at a MOI of 3, and at 48 h postinfection the cells were fixed and stained with anti-chlamydial LPS (red), anti-G3BP1 (green) antibodies and DAPI (blue, nuclei), and viewed under a fluorescence (1–3) or a confocal laser-scanning microscope (4–6). Non-infected cells served as control (1–3). The anti-G3BP1 (1 and 4) and anti-LPS (5) or DAPI (2) signals were merged (3 and 6). A fraction of endogenous G3BP1 is concentrated around chlamydial inclusions (6). Bar = 20 μm.
From: Borth N, Litsche K, Franke C, Sachse K, Saluz HP, Hänel F (2011)
Functional Interaction between Type III-Secreted Protein IncA of Chlamydophila psittaci and Human G3BP1.
PLoS ONE 6(1): e16692.
doi: 10.1371/journal.pone.0016692
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Mouse anti Chlamydia LPS antibody, clone CF 6J12 (MCA2718) used to evaluate Chlamydial LPS expression in Hep-2 cells by western blotting.
Image caption:
Infection of Hep-2 cells with Cp. psittaci leads to a decrease in c-Myc protein concentration.
Hep-2 cells were infected with Cp. psittaci at a MOI of 3, with heat-inactivated Cp. psittaci or chloramphenicol-treated after infection as controls, and at different hours postinfection (hpi) cells were lysed for RNA or protein analysis. (B) Immunoblots of whole cell lysates of Cp. psittaci infected (middle column), infected and chloramphenicol-treated (right) and control (left) cells probed with anti-LPS, anti-c-Myc and anti-β-actin antibodies. Bar diagrams below the immunoblots represent a quantification of c-Myc protein related to β-actin protein concentration. Experiments were performed three times.
From: Borth N, Litsche K, Franke C, Sachse K, Saluz HP, Hänel F (2011)
Functional Interaction between Type III-Secreted Protein IncA of Chlamydophila psittaci and Human G3BP1.
PLoS ONE 6(1): e16692.
doi: 10.1371/journal.pone.0016692
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Mouse anti Chlamydia LPS antibody, clone CF 6J12 (MCA2178) used to evaluate LPS expression in patient biopsies by western blotting.
Image caption:
Western blot analysis of small bowel biopsies from 4 IBS patients against mouse immune sera to LPS and MOMP, respectively. 1-4 = IBS patients, ++ = HeLa cells infected with C. trachomatis (10 μl), + = HeLa cells infected with C. trachomatis (5 μl), - = non-infected HeLa cells.
From: Dlugosz A, Törnblom H, Mohammadian G, Morgan G, Veress B, Edvinsson B, Sandström G, Lindberg G
Chlamydia trachomatis antigens in enteroendocrine cells and macrophages of the small bowel in patients with severe irritable bowel syndrome.
BMC Gastroenterol. 2010 Feb 16;10:19.
doi: 10.1186/1471-230X-10-19.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Mouse anti Chlamydia LPS antibody, clone CF 6J12 (MCA2718) used to demonstrate Chlamydia LPS expression in infected mouse tissues by immunofluorescence.
Image caption:
Chlamydia LPS antibody (MCA 2718, AbD serotec) stained lesion sites in aortic sinus. Chlamydia LPS antibody (MCA 2718, AbD serotec) was used as the first antibody (10 mg/ml), anti-mouse IgG-FITC, developed in sheep, was used as a second antibody. Green represents Chlamydia LPS and blue represents cell nnucleuses stained with 4′,6-diamidino-2-phenylindole (DAPI) (Vector Lab, Peterborogh, UK) [N = 6 mice].
From: Xia M, Chen D, Endresz V, Faludi I, Szabo A, Gonczol E, Kakkar V, Lu X.
Immunization of Chlamydia pneumoniae (Cpn)-infected Apob(tm2Sgy)Ldlr(tm1Her)/J mice with a combined peptide of Cpn significantly reduces atherosclerotic lesion development.
PLoS One. 2013 Dec 13;8(12):e81056.
doi: 10.1371/journal.pone.0081056
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Mouse anti Chlamydia LPS
- Product Type
- Monoclonal Antibody
- Clone
- CF 6J12
- Isotype
- IgG2a
- Specificity
- Chlamydia LPS
Antibody Quality and Performance Guarantee
| Mouse anti Chlamydia LPS antibody, clone CF 6J12 recognizes a genus specific epitope within Chlamydia lipopolysaccharide (LPS). LPS is a common feature of the outer envelope of gram negative bacteria, which acts as a potent endotoxin, triggering an innate immune response. Whilst the LPS of Chlamydia trachomatis does evoke an immune response, it displays only weak endotoxic activity when compared to that of other bacteria such as Salmonella minnesota or Neisseria gonorrhoeae (Ingalls et al. 1995). |
- Target Species
- Bacterial
- Species Cross-Reactivity
-
Target Species Cross Reactivity Chlamydophila sp. - N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG - liquid
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline.
- Preservative Stabilisers
- <0.1% Sodium Azide (NaN3)
- Immunogen
- Elementary bodies from C. trachomatis strain SAF2.
- Approx. Protein Concentrations
- IgG concentration 1.0mg/ml
- Fusion Partners
- Spleen cells from immunised BALB/c mice were fused with cells of the NS0/U mouse myeloma cell line.
- Regulatory
- For research purposes only
- Guarantee
- 12 months from date of despatch
This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |  |
||
| Immunofluorescence | |
||
| Western Blotting | |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Source Reference
-
Thornley, M.J. et al. (1985) Properties of monoclonal antibodies to the genus-specific antigen of Chlamydia and their use for antigen detection by reverse passive haemagglutination.
J Gen Microbiol. 131 (1): 7-15.
References for Chlamydia LPS antibody
-
Campbell, S. et al. (1994) Lipopolysaccharide in cells infected by Chlamydia trachomatis.
Microbiology.140: 1995-2002. -
Dlugosz, A. et al. (2010) Chlamydia trachomatis. antigens in enteroendocrine cells and macrophages of the small bowel in patients with severe irritable bowel syndrome.
BMC Gastroenterol. 10: 19. -
Borth, N. et al. (2011) Functional interaction between type III-secreted protein IncA of Chlamydophila psittaci. and human G3BP1.
PLoS One. 6 (1): e16692. -
Xia, M. et al. (2013) Immunization of Chlamydia pneumoniae. (Cpn)-infected Apob(tm2Sgy)Ldlr(tm1Her)/J mice with a combined peptide of Cpn significantly reduces atherosclerotic lesion development.
PLoS One. 8 (12): e81056. -
Xia M et al. (2013) Immunization of Chlamydia pneumoniae (Cpn)-infected Apob(tm2Sgy)Ldlr(tm1Her)/J mice with a combined peptide of Cpn significantly reduces atherosclerotic lesion development.
PLoS One. 8 (12): e81056. -
Mosolygó, T. et al. (2019) Selenocompounds as Novel Antibacterial Agents and Bacterial Efflux Pump Inhibitors.
Molecules. 24(8):1487. -
Kókai, D. et al. (2021) Ambroxol Treatment Suppresses the Proliferation of Chlamydia pneumoniae in Murine Lungs.
Microorganisms. 9 (4): 880.
Further Reading
-
Ingalls, R.R. et al. (1995) The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated.
Infect Immun. 63 (8): 3125-30.
- RRID
- AB_915244
MCA2718
146557
155720
163779
165381
If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.
View more products with CHLAMYDIA specificity
Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"
View all Anti-Bacterial ProductsAlways be the first to know.
When we launch new products and resources to help you achieve more in the lab.
Yes, sign me up